尿激酶原与阿替普酶治疗急性缺血性脑卒中的疗效对比

Comparative Study on the Efficacy of Prourokinase and Alteplase in the Treatment of Acute Ischemic Stroke

目的:观察尿激酶原与阿替普酶治疗急性缺血性脑卒中(AIS)的疗效。方法:78例AIS患者随机分为对照组和试验组各39例。对照组予阿替普酶治疗,试验组予尿激酶原治疗,比较两组治疗后90 d美国国立卫生研究院卒中量表(NIHSS)评分下降≥4患者比例、改良Rankin量表(mRS)评分0~1患者比例,Barthel指数≥95患者比例;比较两组颅内出血事件发生率。结果:两组患者治疗后24 h及90 d,NIHSS评分下降≥4的患者比例,mRS评分为0~1的患者比例和Barthel指数≥95的患者比例,组间差异均无统计学意义(P>0.05)。两组颅内出血事件发生率分别为12.82%和10.26%,差异无统计学意义(P>0.05)。结论:尿激酶原溶栓治疗AIS的临床疗效确切,且安全性较好,与阿替普酶相当。

Objective: To observe the curative effect of prourokinase compared with that of alteplase on acute ischemic stroke(AIS). Methods: A total of 78 patients with AIS were randomly divided into control group and experimental group. The control group was given alteplase,and the experimental group was given prourokinase. After 90-day treatment,the proportion of patients with decreased NIHSS score≥4,the proportion of patients with modified Rankin scale(mRS) score 0-1 and the proportion of patients with Barthel index≥95 were compared. The incidence of intracranial hemorrhage was also compared between the two groups. Results: As for the proportion of patients with decreased NIHSS score≥4 at 24 h and 90 d after treatment,there was no significant difference between the groups(P>0.05). As for the proportion of patients with mRS score 0-1 and the proportion of patients with Barthel index≥95 at90 d after treatment,there were no significant differences between the two groups as well(P>0.05). The incidence of intracranial hemorrhage was 12.82% in the control group and 10.26% in the experimental group. Conclusion: Prourokinase has a definite clinical efficacy and safety in the treatment of AIS,which is similar to alteplase.